Paris (France) and Cambridge (Massachusetts, United States), March 11, 2026 at 7.30 AM (CET) –
Biophytis SA (Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announces the completion of a capital increase trough the issue of new shares each accompanied by a share subscription warrant, with the removal of the preferential subscription rights of the Company’s existing shareholders in favor of several institutional investors, for a total gross amount of €2,015,000 (the “Issue”). This capital increase was subscribed by a limited number of investors including Alumni Capital for €1,250,000 and Hexagon Capital Fund for €300,000.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer